

January 7, 2022



## Milestone Scientific to Present at the H.C. Wainwright BioConnect 2022 Conference

ROSELAND, N.J., Jan. 07, 2022 (GLOBE NEWSWIRE) -- **Milestone Scientific Inc. (NYSE:MLSS)**, a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced that Arjan Haverhals, Chief Executive Officer of Milestone Scientific, will be presenting at the H.C. Wainwright BioConnect 2022 Conference being held virtually January 10-13, 2022.

Milestone's presentation will be available on-demand to registered attendees via the conference platform beginning Monday, January 10, 2022 at 7:00 AM Eastern Time.

The webcast of the Company's presentation can be accessed here: <https://journey.ct.events/view/d3b75f3c-73e8-45e2-9fc6-d8c0229c9ed5> and on the investor relations section of the Milestone website at <https://www.milestonescientific.com/investors> as of 7:00 AM Eastern Time on Monday, January 10, 2022.

### **About Milestone Scientific Inc.**

Milestone Scientific Inc. (MLSS) is a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific's computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology<sup>®</sup> instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view Milestone Scientific's [brand video](#) or visit [milestonescientific.com](https://www.milestonescientific.com).

### **Safe Harbor Statement**

*This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon*

*management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.*

**Contact:** David Waldman or Natalya Rudman  
Crescendo Communications, LLC  
Email: [mlss@crescendo-ir.com](mailto:mlss@crescendo-ir.com)  
Tel: 212-671-1020



Source: Milestone Scientific, Inc.